Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11901548 | 0.89 | ALDH1A1 (0.51) | ALDH1A1HTTRAB9AALDH3A1EPAS1 | |
| SCHEMBL16657380 | 0.82 | ALDH1A1 (0.65) | ALDH1A1HTTRAB9AALDH3A1EPAS1 | |
| SCHEMBL1337893 | 0.79 | L3MBTL1 (0.68) | ALDH1A1HTTRAB9AALDH3A1EPAS1 | |
| SCHEMBL30615587 | 0.78 | ALDH3A1 (0.53) | ALDH1A1HTTRAB9AALDH3A1EPAS1 | |
| SCHEMBL28495712 | 0.78 | ALDH3A1 (0.53) | ALDH1A1HTTRAB9AALDH3A1EPAS1 | |
| SCHEMBL2507592 | 0.77 | ALDH1A1 (0.48) | ALDH1A1HTTRAB9AALDH3A1EPAS1 | |
| SCHEMBL13937044 | 0.77 | MAPT (0.63) | ALDH1A1HTTRAB9AALDH3A1EPAS1 | |
| SCHEMBL2505880 | 0.75 | EPAS1 (0.46) | ALDH1A1HTTRAB9AEPAS1MEN1 | |
| SCHEMBL2506414 | 0.74 | MAPK14 (0.42) | ALDH1A1L3MBTL1MEN1MAPTKMT2A | |
| SCHEMBL2503937 | 0.73 | MEN1 (0.44) | ALDH1A1HTTRAB9AEPAS1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2552908-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123751-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123751-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ALDH1A1 3905/4885HTT 1338/4885RAB9A 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.